Deflazacort EG Pregnancy

• Pregnancy of Deflazacort EG in details
• Deflazacort EG breastfeeding
• Deflazacort EG reviews

Pregnancy of Deflazacort EG in details

Deflazacort EG crosses the placenta. Orofacial clefts, intrauterine growth restriction, and decreased birth weight have been reported following maternal use. Hypoadrenalism may occur in newborns following maternal use of corticosteroids in pregnancy; monitor.

Deflazacort EG breastfeeding

Corticosteroids have been detected in breast milk in low amounts, however, specific information on this drug in breast milk is unknown. Theoretically, the presence of exogenous corticosteroids in breast milk could suppress growth, interfere with endogenous corticosteroid production, or cause other unwanted effects in breast fed babies, but in doses of up to 50 mg per day, this drug is unlikely to produce a degree of adrenal suppression that would affect the breastfed infant. Higher doses may be expected to affect the degree of adrenal suppression and should be used with caution. There are no data on the effects on milk production.

Benefit should outweigh risk Excreted into human milk: Unknown Comments: Doses of up to 50 mg daily are unlikely to cause systemic effects in the breastfed infant.

See references

References for pregnancy information

1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
2. "Product Information. Emflaza (Deflazacort EG)." Marathon Pharmaceuticals, Deerfield, IL.

References for breastfeeding information

1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
2. "Product Information. Emflaza (Deflazacort EG)." Marathon Pharmaceuticals, Deerfield, IL.

References

1. DailyMed. "DEFLAZACORT: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
2. PubMed Health. "Emflaza: This section provide the link out information of drugs collectetd in PubMed Health. ". http://www.ncbi.nlm.nih.gov/pubmedhe... (accessed September 17, 2018).
3. FDA Pharm Classes. "FDA Pharmacological Classification: FDA published a final rule that amended the requirements for the content and format of approved labeling (prescribing information) for human prescription drug and biological products in January 2006.". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).

Reviews

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name:  Email:  Spam protection:  < Type 19 here

Information checked by Dr. Sachin Kumar, MD Pharmacology